Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.

Short-term Activity Ratios (Summary)
Inventory Turnover
Receivables Turnover
Payables Turnover
Working Capital Turnover
Average Inventory Processing Period
Average Receivable Collection Period
Operating Cycle
Average Payables Payment Period
Cash Conversion Cycle

Gilead Sciences Inc., short-term (operating) activity ratios (quarterly data)

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Turnover Ratios
	Inventory turnover
	Receivables turnover
	Payables turnover
	Working capital turnover
	Average No. Days
	Average inventory processing period
	Add: Average receivable collection period
	Operating cycle
	Less: Average payables payment period
	Cash conversion cycle

Short-term activity ratio	Description	The company
Inventory turnover	An activity ratio calculated as cost of goods sold divided by inventory.	Gilead Sciences Inc.’s inventory turnover ratio deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level.
Receivables turnover	An activity ratio equal to revenue divided by receivables.	Gilead Sciences Inc.’s receivables turnover ratio improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.
Payables turnover	An activity ratio calculated as cost of goods sold divided by payables.	Gilead Sciences Inc.’s payables turnover ratio increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Working capital turnover	An activity ratio calculated as revenue divided by working capital.	Gilead Sciences Inc.’s working capital turnover ratio improved from Q1 2020 to Q2 2020 but then deteriorated significantly from Q2 2020 to Q3 2020.

Short-term activity ratio	Description	The company
Average inventory processing period	An activity ratio equal to the number of days in the period divided by inventory turnover over the period.	Gilead Sciences Inc.’s number of days of inventory outstanding deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level.
Average receivable collection period	An activity ratio equal to the number of days in the period divided by receivables turnover.	Gilead Sciences Inc.’s number of days of receivables outstanding improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.
Operating cycle	Equal to average inventory processing period plus average receivables collection period.	Gilead Sciences Inc.’s operating cycle improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.
Average payables payment period	An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period.	Gilead Sciences Inc.’s number of days of payables outstanding decreased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.
Cash conversion cycle	A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period.	Gilead Sciences Inc.’s cash conversion cycle improved from Q1 2020 to Q2 2020 but then deteriorated significantly from Q2 2020 to Q3 2020.

Gilead Sciences Inc., inventory turnover calculation (quarterly data)

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Selected Financial Data (US$ in millions)
	Cost of goods sold
	Inventories
	Short-term Activity Ratio
	Inventory turnover¹
	Benchmarks
	Inventory Turnover, Competitors²
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Eli Lilly & Co.
	Illumina Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Q3 2020 Calculation
Inventory turnover = (Cost of goods sold_{Q3 2020} + Cost of goods sold_{Q2 2020} + Cost of goods sold_{Q1 2020} + Cost of goods sold_{Q4 2019}) ÷ Inventories
= ( + + + ) ÷ =

² Click competitor name to see calculations.

Short-term activity ratio	Description	The company
Inventory turnover	An activity ratio calculated as cost of goods sold divided by inventory.	Gilead Sciences Inc.’s inventory turnover ratio deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level.

Gilead Sciences Inc., receivables turnover calculation (quarterly data)

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Selected Financial Data (US$ in millions)
	Product sales
	Accounts receivable, net of allowances
	Short-term Activity Ratio
	Receivables turnover¹
	Benchmarks
	Receivables Turnover, Competitors²
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Eli Lilly & Co.
	Illumina Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Q3 2020 Calculation
Receivables turnover = (Product sales_{Q3 2020} + Product sales_{Q2 2020} + Product sales_{Q1 2020} + Product sales_{Q4 2019}) ÷ Accounts receivable, net of allowances
= ( + + + ) ÷ =

² Click competitor name to see calculations.

Short-term activity ratio	Description	The company
Receivables turnover	An activity ratio equal to revenue divided by receivables.	Gilead Sciences Inc.’s receivables turnover ratio improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.

Gilead Sciences Inc., payables turnover calculation (quarterly data)

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Selected Financial Data (US$ in millions)
	Cost of goods sold
	Accounts payable
	Short-term Activity Ratio
	Payables turnover¹
	Benchmarks
	Payables Turnover, Competitors²
	Abbott Laboratories
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Eli Lilly & Co.
	Illumina Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Q3 2020 Calculation
Payables turnover = (Cost of goods sold_{Q3 2020} + Cost of goods sold_{Q2 2020} + Cost of goods sold_{Q1 2020} + Cost of goods sold_{Q4 2019}) ÷ Accounts payable
= ( + + + ) ÷ =

² Click competitor name to see calculations.

Short-term activity ratio	Description	The company
Payables turnover	An activity ratio calculated as cost of goods sold divided by payables.	Gilead Sciences Inc.’s payables turnover ratio increased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.

Gilead Sciences Inc., working capital turnover calculation (quarterly data)

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Selected Financial Data (US$ in millions)
	Current assets
	Less: Current liabilities
	Working capital

	Product sales
	Short-term Activity Ratio
	Working capital turnover¹
	Benchmarks
	Working Capital Turnover, Competitors²
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Eli Lilly & Co.
	Illumina Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Q3 2020 Calculation
Working capital turnover = (Product sales_{Q3 2020} + Product sales_{Q2 2020} + Product sales_{Q1 2020} + Product sales_{Q4 2019}) ÷ Working capital
= ( + + + ) ÷ =

² Click competitor name to see calculations.

Short-term activity ratio	Description	The company
Working capital turnover	An activity ratio calculated as revenue divided by working capital.	Gilead Sciences Inc.’s working capital turnover ratio improved from Q1 2020 to Q2 2020 but then deteriorated significantly from Q2 2020 to Q3 2020.

Gilead Sciences Inc., average inventory processing period calculation (quarterly data)

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Selected Financial Data
	Inventory turnover
	Short-term Activity Ratio (no. days)
	Average inventory processing period¹
	Benchmarks (no. days)
	Average Inventory Processing Period, Competitors²
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Eli Lilly & Co.
	Illumina Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Q3 2020 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

² Click competitor name to see calculations.

Short-term activity ratio	Description	The company
Average inventory processing period	An activity ratio equal to the number of days in the period divided by inventory turnover over the period.	Gilead Sciences Inc.’s number of days of inventory outstanding deteriorated from Q1 2020 to Q2 2020 but then improved from Q2 2020 to Q3 2020 exceeding Q1 2020 level.

Gilead Sciences Inc., average receivable collection period calculation (quarterly data)

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Selected Financial Data
	Receivables turnover
	Short-term Activity Ratio (no. days)
	Average receivable collection period¹
	Benchmarks (no. days)
	Average Receivable Collection Period, Competitors²
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Eli Lilly & Co.
	Illumina Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Q3 2020 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

² Click competitor name to see calculations.

Short-term activity ratio	Description	The company
Average receivable collection period	An activity ratio equal to the number of days in the period divided by receivables turnover.	Gilead Sciences Inc.’s number of days of receivables outstanding improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.

Gilead Sciences Inc., operating cycle calculation (quarterly data)

No. days

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Selected Financial Data
	Average inventory processing period
	Average receivable collection period
	Short-term Activity Ratio
	Operating cycle¹
	Benchmarks
	Operating Cycle, Competitors²
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Biogen Inc.
	Eli Lilly & Co.
	Illumina Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Q3 2020 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

² Click competitor name to see calculations.

Short-term activity ratio	Description	The company
Operating cycle	Equal to average inventory processing period plus average receivables collection period.	Gilead Sciences Inc.’s operating cycle improved from Q1 2020 to Q2 2020 but then slightly deteriorated from Q2 2020 to Q3 2020 not reaching Q1 2020 level.

Gilead Sciences Inc., average payables payment period calculation (quarterly data)

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Selected Financial Data
	Payables turnover
	Short-term Activity Ratio (no. days)
	Average payables payment period¹
	Benchmarks (no. days)
	Average Payables Payment Period, Competitors²
	Abbott Laboratories
	Amgen Inc.
	Biogen Inc.
	Bristol-Myers Squibb Co.
	Eli Lilly & Co.
	Illumina Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Q3 2020 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

² Click competitor name to see calculations.

Short-term activity ratio	Description	The company
Average payables payment period	An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period.	Gilead Sciences Inc.’s number of days of payables outstanding decreased from Q1 2020 to Q2 2020 and from Q2 2020 to Q3 2020.

Gilead Sciences Inc., cash conversion cycle calculation (quarterly data)

No. days

		Sep 30, 2020	Jun 30, 2020	Mar 31, 2020		Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019		Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018		Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017		Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016		Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
	Selected Financial Data
	Average inventory processing period
	Average receivable collection period
	Average payables payment period
	Short-term Activity Ratio
	Cash conversion cycle¹
	Benchmarks
	Cash Conversion Cycle, Competitors²
	Abbott Laboratories
	Amgen Inc.
	Biogen Inc.
	Eli Lilly & Co.
	Illumina Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Q3 2020 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =

² Click competitor name to see calculations.

Short-term activity ratio	Description	The company
Cash conversion cycle	A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period.	Gilead Sciences Inc.’s cash conversion cycle improved from Q1 2020 to Q2 2020 but then deteriorated significantly from Q2 2020 to Q3 2020.

	Gilead Sciences Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Short-term Activity Ratios (Summary)

Inventory Turnover

Receivables Turnover

Payables Turnover

Working Capital Turnover

Average Inventory Processing Period

Average Receivable Collection Period

Operating Cycle

Average Payables Payment Period

Cash Conversion Cycle

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Short-term (Operating) Activity RatiosQuarterly Data

Short-term Activity Ratios (Summary)

Inventory Turnover

Receivables Turnover

Payables Turnover

Working Capital Turnover

Average Inventory Processing Period

Average Receivable Collection Period

Operating Cycle

Average Payables Payment Period

Cash Conversion Cycle

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data